JP2004501104A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2004501104A5 JP2004501104A5 JP2001585739A JP2001585739A JP2004501104A5 JP 2004501104 A5 JP2004501104 A5 JP 2004501104A5 JP 2001585739 A JP2001585739 A JP 2001585739A JP 2001585739 A JP2001585739 A JP 2001585739A JP 2004501104 A5 JP2004501104 A5 JP 2004501104A5
- Authority
- JP
- Japan
- Prior art keywords
- treatment
- minutes
- zoledronic acid
- treatment agent
- over
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- XRASPMIURGNCCH-UHFFFAOYSA-N zoledronic acid Chemical compound OP(=O)(O)C(P(O)(O)=O)(O)CN1C=CN=C1 XRASPMIURGNCCH-UHFFFAOYSA-N 0.000 description 13
- 239000003795 chemical substances by application Substances 0.000 description 11
- 238000000034 method Methods 0.000 description 9
- 229960004276 zoledronic acid Drugs 0.000 description 8
- 150000003839 salts Chemical class 0.000 description 6
- 229940122361 Bisphosphonate Drugs 0.000 description 5
- 208000037147 Hypercalcaemia Diseases 0.000 description 5
- 150000004663 bisphosphonates Chemical class 0.000 description 5
- 230000000148 hypercalcaemia Effects 0.000 description 5
- 208000030915 hypercalcemia disease Diseases 0.000 description 5
- 206010028980 Neoplasm Diseases 0.000 description 3
- 210000000988 bone and bone Anatomy 0.000 description 3
- 238000001990 intravenous administration Methods 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- 206010027476 Metastases Diseases 0.000 description 2
- 208000034578 Multiple myelomas Diseases 0.000 description 2
- CZYWHNTUXNGDGR-UHFFFAOYSA-L Pamidronate disodium Chemical compound O.O.O.O.O.[Na+].[Na+].NCCC(O)(P(O)([O-])=O)P(O)([O-])=O CZYWHNTUXNGDGR-UHFFFAOYSA-L 0.000 description 2
- 206010035226 Plasma cell myeloma Diseases 0.000 description 2
- 150000001768 cations Chemical class 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- -1 imidazol-l-yl Chemical group 0.000 description 2
- 230000009401 metastasis Effects 0.000 description 2
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 206010027452 Metastases to bone Diseases 0.000 description 1
- ABLZXFCXXLZCGV-UHFFFAOYSA-N Phosphorous acid Chemical compound OP(O)=O ABLZXFCXXLZCGV-UHFFFAOYSA-N 0.000 description 1
- 208000025865 Ulcer Diseases 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 230000033115 angiogenesis Effects 0.000 description 1
- 229910052739 hydrogen Inorganic materials 0.000 description 1
- 239000001257 hydrogen Substances 0.000 description 1
- 125000002962 imidazol-1-yl group Chemical group [*]N1C([H])=NC([H])=C1[H] 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 239000003978 infusion fluid Substances 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 208000030159 metabolic disease Diseases 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 159000000000 sodium salts Chemical class 0.000 description 1
- 238000011272 standard treatment Methods 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 230000005747 tumor angiogenesis Effects 0.000 description 1
- 231100000397 ulcer Toxicity 0.000 description 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB0012209.3A GB0012209D0 (en) | 2000-05-19 | 2000-05-19 | Organic compounds |
| PCT/US2001/014886 WO2001089494A2 (en) | 2000-05-19 | 2001-05-09 | Use of zolendronate for the manufacture of a medicament for the treatment of bone metabolism diseases |
Related Child Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2012053573A Division JP2012162531A (ja) | 2000-05-19 | 2012-03-09 | 骨代謝疾患の処置のための医薬の製造のための、ゾレドロネートの使用 |
| JP2013086245A Division JP2013151553A (ja) | 2000-05-19 | 2013-04-17 | 骨代謝疾患の処置のための医薬の製造のための、ゾレドロネートの使用 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2004501104A JP2004501104A (ja) | 2004-01-15 |
| JP2004501104A5 true JP2004501104A5 (enExample) | 2012-04-26 |
Family
ID=9891987
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2001585739A Withdrawn JP2004501104A (ja) | 2000-05-19 | 2001-05-09 | 骨代謝疾患の処置のための医薬の製造のための、ゾレドロネートの使用 |
| JP2012053573A Withdrawn JP2012162531A (ja) | 2000-05-19 | 2012-03-09 | 骨代謝疾患の処置のための医薬の製造のための、ゾレドロネートの使用 |
| JP2013086245A Pending JP2013151553A (ja) | 2000-05-19 | 2013-04-17 | 骨代謝疾患の処置のための医薬の製造のための、ゾレドロネートの使用 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2012053573A Withdrawn JP2012162531A (ja) | 2000-05-19 | 2012-03-09 | 骨代謝疾患の処置のための医薬の製造のための、ゾレドロネートの使用 |
| JP2013086245A Pending JP2013151553A (ja) | 2000-05-19 | 2013-04-17 | 骨代謝疾患の処置のための医薬の製造のための、ゾレドロネートの使用 |
Country Status (9)
| Country | Link |
|---|---|
| EP (1) | EP1286665B1 (enExample) |
| JP (3) | JP2004501104A (enExample) |
| CN (1) | CN100389772C (enExample) |
| AU (2) | AU6128301A (enExample) |
| BR (1) | BR0110913A (enExample) |
| CA (1) | CA2409930C (enExample) |
| ES (1) | ES2409033T3 (enExample) |
| GB (1) | GB0012209D0 (enExample) |
| WO (1) | WO2001089494A2 (enExample) |
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20040014724A1 (en) | 2001-05-09 | 2004-01-22 | Seaman John J. | Method of administering a bisphosphonate |
| DE60113537T3 (de) | 2000-06-20 | 2013-05-29 | Novartis Ag | Methode zur verabreichung von biphosphonaten |
| DE60317061T2 (de) | 2002-05-10 | 2008-07-24 | F. Hoffmann-La Roche Ag | Ibandronsäure zur behandlung und vorbeugung von osteoporose |
| CN1681516A (zh) * | 2002-09-16 | 2005-10-12 | 诺瓦提斯公司 | 预防或减少髋部骨折后继发性骨折的方法 |
| EP1596870B2 (en) | 2002-12-20 | 2011-04-06 | F. Hoffmann-La Roche AG | High dose ibandronate formulation |
| MY141763A (en) * | 2003-09-18 | 2010-06-30 | Novartis Ag | Pharmaceutical products comprising bisphosphonates |
| US7511152B2 (en) | 2004-12-09 | 2009-03-31 | Merck & Co., Inc. | Estrogen receptor modulators |
| ES2391573T3 (es) * | 2005-09-08 | 2012-11-27 | Medinet Co., Ltd. | Método para el tratamiento de activación de una célula presentadora de antígeno |
| EP2268301B1 (en) * | 2008-01-24 | 2020-02-26 | Remedor Biomed Ltd. | Erythropoietin and fibronectin compositions for bone regeneration |
| PL2473172T3 (pl) | 2009-09-01 | 2015-08-31 | Univ Duke | Kompozycje bisfosfonianowe i sposoby do leczenia niewydolności serca |
| CN102000035B (zh) * | 2010-10-13 | 2012-07-25 | 江苏奥赛康药业股份有限公司 | 一种供注射用的唑来膦酸组合物及其制备方法 |
| JP6261512B2 (ja) | 2011-11-16 | 2018-01-17 | デューク ユニバーシティ | 心機能障害を治療及び／又は低減するためのビスホスホネート組成物並びに方法 |
| RU2519120C1 (ru) * | 2012-11-06 | 2014-06-10 | Федеральное государственное бюджетное учреждение "Ростовский научно-исследовательский онкологический институт" Министерства здравоохранения Российской Федерации | Способ профилактики скелетных осложнений у больных с литическими метастазами в плоские и смешанные кости |
| DE102014004512A1 (de) * | 2014-03-28 | 2015-10-01 | Georg-August-Universität Göttingen Stiftung Öffentlichen Rechts Bereich Universitätsmedizin | Anorganisch-organische Hybridverbindung |
| BE1021270B1 (nl) * | 2014-06-17 | 2015-10-14 | Neogen N.V. | Zoledronine oplossing |
| CN105213407B (zh) | 2015-07-01 | 2018-01-02 | 南京大学 | 唑来膦酸用于制备治疗脂肪性肝病的药物的用途 |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20040014724A1 (en) | 2001-05-09 | 2004-01-22 | Seaman John J. | Method of administering a bisphosphonate |
-
2000
- 2000-05-19 GB GBGB0012209.3A patent/GB0012209D0/en not_active Ceased
-
2001
- 2001-05-09 CA CA2409930A patent/CA2409930C/en not_active Expired - Fee Related
- 2001-05-09 ES ES01935167T patent/ES2409033T3/es not_active Expired - Lifetime
- 2001-05-09 BR BR0110913-8A patent/BR0110913A/pt not_active Application Discontinuation
- 2001-05-09 CN CNB018097812A patent/CN100389772C/zh not_active Ceased
- 2001-05-09 JP JP2001585739A patent/JP2004501104A/ja not_active Withdrawn
- 2001-05-09 AU AU6128301A patent/AU6128301A/xx active Pending
- 2001-05-09 EP EP01935167.5A patent/EP1286665B1/en not_active Revoked
- 2001-05-09 AU AU2001261283A patent/AU2001261283B2/en not_active Expired
- 2001-05-09 WO PCT/US2001/014886 patent/WO2001089494A2/en not_active Ceased
-
2012
- 2012-03-09 JP JP2012053573A patent/JP2012162531A/ja not_active Withdrawn
-
2013
- 2013-04-17 JP JP2013086245A patent/JP2013151553A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2004501104A5 (enExample) | ||
| RU2325913C2 (ru) | Применение золедроновой кислоты, ее солей, гидратов и способ антиноцицептивного или антиаллодинического лечения боли, способ лечения невропатической боли | |
| JP2012162531A (ja) | 骨代謝疾患の処置のための医薬の製造のための、ゾレドロネートの使用 | |
| RU94046316A (ru) | Применение высокоэффективных фосфонатов при изготовлении лекарственных средств для лечения остеопороза | |
| AU775079B2 (en) | Pharmaceutical compositions and uses | |
| JP2015083592A (ja) | 骨粗鬆症の治療および予防用のビスホスホン酸 | |
| WO1995028145A1 (en) | Iontophoretic delivery of bisphosphonates to the alveolar bone | |
| CN1327844C (zh) | 包含双膦酸类化合物和hmg－coa还原酶抑制剂的组合疗法 | |
| AU2001261283A1 (en) | Use of zolendronate for the manufacture of a medicament for the treatment of bone metabolism diseases | |
| US7148210B2 (en) | Method of treating bone metastasis | |
| NZ250293A (en) | Fracture treatment using methanebisphosphonic acid derivatives and pharmaceutical compositions | |
| US8324189B2 (en) | Use of zolendronate for the manufacture of a medicament for the treatment of bone metabolism diseases | |
| EP1165139A2 (en) | Pharmaceutical compositions comprising in combination a bisphosphonate and a matrix metalloproteinasese inhibitor | |
| Burckhardt et al. | Treatment of Paget’s disease with short courses of bisphosphonates | |
| JPH08277223A (ja) | 高カルシウム血症治療のための薬剤 | |
| Heatley | Metastatic bone disease and tumour-induced hypercalcaemia: the role of bisphosphonates | |
| Harvengt | Epanolol-Clodronate dinatrium | |
| Saag et al. | Zoledronic acid 5 mg IV produces more rapid reduction in bone resorption markers compared to weekly 70 mg oral alendronate in post-menopausal women with osteoporosis/osteopenia | |
| Babbitt et al. | Monthly oral ibandronate and quarterly ibandronate injections have comparable adherence rates in patients with GI intolerance to weekly bisphosphonates | |
| HK1080734B (en) | Combination therapy comprising a bisphosphonate and a hmg-coa reductase inhibitor |